In Australia, there were more than 1 million hospitalizations in 2016 resulting from diabetes with disproportionately higher rates of hospitalization among Indigenous Australians compared with non-Indigenous counterparts \[[@CIT0001]\]. Aboriginal and Torres Strait Islander Australians (ATSI) are 8 times more likely to have diabetes \[[@CIT0001]\]. Although optimal glycemic control is needed to prevent chronic complications, diabetic patients on treatment are at risk of hypoglycemia, defined as a blood glucose level ≤ 3.9 mmol/L (≤70 mg/dL). Both inpatient and outpatient trials have shown that the risk of hypoglycemia limits achievement of good blood glucose control \[[@CIT0002]\].

Several studies have shown an association between severe hypoglycemia and all-cause mortality \[[@CIT0002], [@CIT0003]\]. Despite well-studied consequences of low blood glucose levels in critically ill admissions \[[@CIT0004]\], the effect of hypoglycemia on outcomes in non-Caucasian cohorts in general is least studied \[[@CIT0008]\]. Some studies have shown that general ward hypoglycemia in hospitalized Caucasian patients with diabetes is associated with increase in length of stay (LOS) \[[@CIT0009]\], mortality \[[@CIT0002], [@CIT0003], [@CIT0009]\], and costs \[[@CIT0010]\] but extrapolation of these data onto indigenous subpopulations might not be realistic. Some of these studies suggest that the increased mortality is not associated with the hypoglycemia itself but rather with the patients' comorbidities \[[@CIT0002], [@CIT0003]\]. Furthermore, despite a high prevalence of diabetes and its complications among the Australian Indigenous population, there is no study on effects of inpatient hypoglycemia in its diabetic population.

The aim of this study was to evaluate outcomes of inpatient hypoglycemia in diabetic indigenous compared to non-Indigenous Australians.

1. Methods {#s1}
==========

Data from patients with diabetes who were admitted to a 775-bed teaching hospital between April 1, 2015, and March 31, 2016, were reviewed. The study was based on a retrospective audit carried out using the National Health Roundtable (NHR) registry, electronic medical record, and laboratory data (Auslab) provided by the hospital's Medication Safety Committee and the study was approved by the regional ethics committee. The NHR database contains clinical information complemented by manual extraction of medication and laboratory details from the electronic medical record and Auslab, respectively. Adult patients aged \> 18 years admitted to the hospital's general wards were included in the study. Information extracted includes gender, age, primary and secondary diagnoses according to the International Classification of Diseases, Ninth Revision, Clinical Modification code showing admission and discharge status, LOS, indigenous status (dichotomized as ATSI and non-ATSI). Medications for diabetes (insulin and/or oral hypoglycemic agents) and blood glucose (point of care and/or laboratory) levels were also collated and analyzed.

The NHR database also contains a field that identifies readmission within the 30-day period after discharge. The readmission variable is a new hospitalization in the month following discharge with the same major diagnostic category as the initial diagnosis. The analysis includes patients discharged within the period of the study with a primary or secondary diagnosis of diabetes and a secondary diagnosis of hypoglycemia. Analysis also included demographic characteristics and the presence or absence of coexisting conditions, including congestive heart, coronary heart disease, hypercholesterolemia, chronic renal failure, exacerbation of chronic pulmonary disease, atrial fibrillation, cerebrovascular disease, dementia, gastric hemorrhagic bleeding, neoplasm, hypertension, anemia, nursing home residence, peripheral arterial disease, malnutrition, obesity, and cirrhosis. A diagnosis was considered primary if it was the reason for admission; all other diagnoses were considered secondary.

Descriptive analyses for demographic and clinical characteristics were presented as means and SDs for continuous variables and frequencies and percentages for categorical variables. We used the Charlson Comorbidity Index (CCI) \[[@CIT0011]\] to rank patient illness severity based on the number and importance of comorbid diseases. The overall comorbidity score ranges were calculated showing the cumulative increased likelihood of 1-year mortality. CCI contains 19 groups of comorbidities, each weighted 1 to 6 to reflect their potential influence on mortality. Furthermore, patients were classified into groups based on their total CCI scores (mild: 1, 2; moderate, 3, 4; severe, ≥5); hypoglycemia was classified based on lowest blood glucose values and categorized as previously described \[[@CIT0012]\]: mild (3.9-3.1 mmol/L; 70.0-55.0 mg/dL), moderate (3.0-2.3 mmol/L; 54.0-40.0 mg/dL), and severe (≤ 2.2 mmol\\L; ≤ 40.0 mg/dL).

Associations between all explanatory variables and categorical response variables (inpatient mortality and the likelihood of readmission) were assessed separately using univariate logistic regression as preliminary analysis. Multivariable logistic regression was applied to inpatient mortality and readmission separately to investigate their association with hypoglycemia while adjusting for age, gender, indigenous status, lowest blood glucose level (BGL) during hypoglycemic event and the Charlson index score. Adjusted odds ratios and 95% confidence interval (CI) were presented for categorical variables. The survival risk (hazard ratio \[HR\]) was computed with the HR estimated from the Cox regression model. In this study, survival refers to patients who survived after being discharged from the hospital.

Because of the small events size and limited data, we used Firth penalized likelihood method to fit the logistic models and Cox regression. Inference was based on 5% level of significance and all statistical analyses was performed in SAS 9.4 software (SAS Institute Inc., Cary, NC) and R statistical software (R Foundation for Statistical Computing, Vienna, Austria).

2. Results {#s2}
==========

A total of 6027 patients were admitted during the period of the study. We identified 1618 patients admitted with diabetes, representing 23.7% of the total ward admissions. Of these, hypoglycemic events were documented in 484 patients (29.9%). A follow-up retrospective study of a cohort of 91 patients whose data were available for review and fulfilled inclusion criteria were analyzed. We present in [Table 1](#T1){ref-type="table"} the baseline demographic and clinical characteristics of the study population. The age range of the cohort was 21 to 87 years old (mean, 60.6 years), males 51.6% and had type 2 diabetes (96.7%). Among the patients, 30 (33.0%) were identified as ATSI and 70.3% of them were on insulin. The mean lowest BGL was 2.9 mmol/L (52.2 mg/dL) (range, 1.1-3.9 mmol/L; 20.0-70.0 mg/dL). A total of 44 (48.3%) patients had lowest BGL between 3.9 mmol/L (70.0 mg/dL) and 3.1 mmol/L (55.0 mg/dL), 28 (30.8%) had BGL between 3.0 mmol/L (54 mg/dL) and 2.3 mmol/L (41.0 mg/dL), whereas the remaining 19 (20.9%) patient had a BGL ≤ 2.2 mmol/L (≤ 40 mg/dL) during their hospitalization. The mean number of hypoglycemic events with inpatient hypoglycemia was 2.9 episodes/patient (range, 1-15 episodes/patient).

###### 

Demographic and Clinical Characteristics of Patients with Hypoglycemia

  Characteristics                 Mean (Range) or N (%)^*a*^   Readmission OR (95% CI)   Mortality OR (95% CI)
  ------------------------------- ---------------------------- ------------------------- -----------------------
  **Overall**                     **91**                       **20 (22.0%)**            **6 (6.6%)**
  Gender                                                                                 
   Male                           47 (51.6%)                   0.9 (0.3--2.5)            0.2 (0.0--1.2)
   Female                         44 (48.4%)                   Reference                 Reference
   Age (years)                    60.6 (21--87)                1.0 (0.9--1.0)            1.0 (0.9--1.0)
  Age                                                                                    
    \< 50 years                   21 (23.1%)                   Reference                 Reference
   50--59 years                   19 (20.9%)                   0.1 (0.0--0.5)            2.9 (0.4--32.1)
   60--69 years                   24 (26.4%)                   0.3 (0.1--1.1)            1.5 (0.2--17.6)
   70+ years                      27 (29.7%)                   0.2 (0.1--0.7)            0.3 (0.0--4.9)
  Surgical procedure              18 (19.8%)                   1.1 (0.3--3.4)            0.5 (0.1--5.3)
  No surgical procedure           73 (80.2%)                   Reference                 Reference
  Indigenous status^*b*^                                                                 
   ATSI                           30 (33.0%)                   0.9 (0.3--2.4)            0.5 (0.1--2.8)
   Non-ATSI                       61 (67.0%)                   Reference                 Reference
  LOS                             9.0 (0.3--49.7)                                        
  Number of hypoglycemia          2.9 \[1--15\]                0.8 (0.5--1.0)            1.0 (0.5--1.2)
  Mean lowest BGL                 2.9 (1.1--3.9)               0.9 (0.4--1.8)            1.6 (0.5--6.5)
  BGL group                                                                              
   Mild (3.9--3.1 mmol/L)         44 (48.3%)                   Reference                 Reference
   Moderate (3.0--2.3 mmol/L)     28 (30.8%)                   0.8 (0.2--2.4)            1.6 (0.3--8.2)
   Severe (≤ 2.2 mmol/L)          19 (20.9%)                   1.2 (0.4--4.1)            0.3 (0.0--3.4)
  CCI                             7.2 \[1--15\]                0.9 (0.7--1.0)            1.1 (0.9--1.5)
  CCI subgroups                                                                          
   Mild: CCI score \[1, 2\]       6 (6.6%)                     Reference                 Reference
   Moderate: CCI score \[3, 4\]   6 (6.6%)                     0.1 (0.0--2.5)            1.0 (0.0--81.0)
   Severe: CCI score (≥ 5)        79 (86.8%)                   0.3 (0.1--1.5)            1.2 (0.5--28.5)
  Number on insulin               66 (77.7%)                   5.5 (0.9--32.6)           0.3 (0.1--1.4)
  Hospital diabetes treatment                                                            
   Basal only                     10 (11.0%)                   Reference                 Reference
   Basal + bolus                  33 (36.3%)                   1.0 (0.2--4.6)            2.4 (0.2--34.4)
   Mixed                          26 (28.6%)                   0.7 (0.2--3.4)            0.4 (0.0--75.5)
   Unknown                        22 (24.2%)                                             
  Types of diabetes                                                                      
   T2DM                           58 (63.7%)                                             
   T1DM                           29 (31.8%)                                             
   Unknown                        4 (4.4%)                                               

All the listed categories and variables were not statistically significant.

ATSI, Aboriginal and Torres Strait Islander Australians; BGL, blood glucose level; CCI, Carlson comorbidity index; CI, confidence interval; LOS, length of stay; OR, odds ratio; T1DM, type diabetes mellitus; T2DM, type 2 diabetes mellitus.

^*a*^Number of events (percentage).

^*b*^Aboriginal and/or Torres Strait Islander.

This cohort of patients shows a higher burden of comorbidity with an average CCI score of 7.2 (range, 1-15) and 86.81% had a CCI of ≥ 5. The mean LOS was 9.0 days (range, 0.3-49.7). About one-third (36.3%) of the patients were treated with basal-bolus insulin regimen. [Table 1](#T1){ref-type="table"} reveals no significant associations between baseline demographic (and clinical) characteristics and readmission (and mortality). About one-half (53.9%) of the patients in this cohort had hypertension; other primary diagnosis and major comorbidities are presented in [Table 2](#T2){ref-type="table"}. Further summary of the data and the data fields are included in [Table 3](#T3){ref-type="table"}. Although non-ATSI had higher mortality and readmission, quantitative comparisons with ATSI were not statistically significant. We observed that, separately, comorbidity rates, LOS, and number hypoglycemia were significantly higher for non-ATSI than ATSI ([Table 3](#T3){ref-type="table"}).

###### 

Characteristics of Subjects with Inpatient Hypoglycemia Showing Primary Diagnoses and Major Comorbidities at the Time of Admission

  Variables                          n    \%
  ---------------------------------- ---- -------
  Primary diagnosis                       
   Infection                         27   29.67
   Metabolic                         24   26.37
   Cardiovascular                    14   13.38
   Cancer                            10   10.99
   Mental                            6    6.59
   Musculoskeletal                   10   10.99
  Comorbidities^*a*^                      
   Hypertension                      49   53.85
   Ischemic heart disease            25   27.47
   Dyslipidemia                      23   25.27
   Osteoarthritis                    15   16.48
   Depression                        13   14.29
   Stroke                            8    8.79
   Gastroesophageal reflux disease   9    9.89

^*a*^Including those with multiple comorbidities

###### 

Demographic and Clinical Characteristics of Patients with Hypoglycemia Among ATSI^*a*^ and Non-ATSI

  Characteristics                        Total             Non-ATSI^*a*^      ATSI^*a*^
  -------------------------------------- ----------------- ------------------ -----------------------
  Overall, n (%)                         91                61(67.0%)          30 (33.0%)^*b*^
  Mortality                              6 (6.6%)          5 (83.3%)          1 (16.7%)
  Readmission                            20 (3.0%)         14 (70.0%)         6 (30.0%)
  Gender, n (%)                                                               
   Male                                  47 (51.6%)        36 (76.6%)         11 (23.4%)
   Female                                44 (48.4%)        25 (56.8%)         19 (43.2%)
  Age, n (%)                                                                  
    \< 50 years                          21 (23.1%)        13 (61.9%)         8 (38.1%)
   50--59 years                          19 (20.9%)        8 (42.1%)          11 (57.9%)
   60--69 years                          24 (26.4%)        17 (70.8%)         7 (29.2%)
   70+ years                             27 (29.7%)        23 (85.2%)         4 (14.8%)
  Surgical procedure, n (%)              18 (19.8%)        11 (61.1%)         7 (38.9%)^*b*^
  No surgical procedure, n (%)           73 (80.2%)        52 (71.3%)         21 (28.8%)
  BGL group, n (%)                                                            
   Mild (3.9--3.1 mmol/L)                44 (48.3%)        29 (65.9%)         15 (34.1%)
   Moderate (3.0--2.3 mmol/L)            28 (30.8%)        18 (64.3%)         10 (35.3%)^*c*^
   Severe (≤ 2.2 mmol/L)                 19 (20.9%)        14 (73.7%)         5 (26.3%)^*c*^
  CCI subgroups, n (%)                                                        
   Mild: CCI score \[1, 2\]              6 (6.6%)          3 (50.0%)          3 (50.0%)
   Moderate: CCI score \[3, 4\]          6 (6.6%)          4 (66.7%)          2 (33.3%)
   Severe: CCI score (≥ 5)               79 (86.8%)        54 (68.4%)         25 (31.7%)^*b*^
  Age (years)                            60.6 (21--87)     63.4 (27--9)       55 (21--8)^*b*^
  LOS, mean (range)                      9.0 (0.3--49.7)   10.9 (0.6--49.7)   5.17 (0.3--13.4)^*d*^
  Number of hypoglycemia, mean (range)   2.9 \[1--15\]     3.5 \[1--15\]      2.0 \[1--6\]^*c*^
  Mean lowest BGL, mean (range)          2.9 (1.1--3.9)    7.4 \[1--14\]      7.2 \[1--15\]
  CCI, mean (range)                      7.24 \[1--15\]    7.4 \[1--14\]      2.9 (1.3--3.9)

ATSI, Aboriginal and/or Torres Strait Islander; BGL, blood glucose level; CCI, Carlson comorbidity index; LOS, length of stay.

^*a*^Based on the number of events within each category. Note that the first subcategory of a variable is the reference comparison.

^*b*^ *P* \< 0.05.

^*c*^ *P* \< 0.01.

^*d*^ *P* \< 0.001.

The adjusted model for likelihood of readmission showed that gender, indigenous status, CCI, and BGL level were not significant risk factors for an increased readmission ([Table 4](#T4){ref-type="table"}). Having a CCI score between 3 and 4 did not reach nominal statistical significance (*P* = 0.06). However, readmitted patients were older (50-59 years vs \< 50 years, *P* = \< 0.05; 60-69 years vs \< 50 years, *P* = \< 0.12; 70 + years vs \< 50 years, *P* = \<0.05).

###### 

Risk Factors for Readmission and Length of Hospital Stay Among Diabetic Subjects with Inpatient Hypoglycemia

  Characteristics                                Readmission           Length of stay
  ---------------------------------------------- --------------------- ---------------------
  Gender (reference: female)                                           
  Male                                           1.2 (0.4--3.7)        0.8 (0.5--1.3)
  Indigenous status (reference: NATSI)                                 
  ATSI                                           0.9 (0.3--2.8)        2.1 (1.2--3.5)^*a*^
  Age (reference: \<50 years)                                          
   50--59 years                                  0.1 (0--0.6)^*b*^     0.7 (0.4--1.5)
   60--69 years                                  0.3 (0.1--1.2)        0.8 (0.4--1.7)
   70+ years                                     0.2 (0.1--0.8)^*b*^   0.7 (0.3--1.3)
  CCI (reference: mild CCI score, 1--2)                                
   Moderate: CCI score \[3, 4\]                  0.1 (0--3.6)          0.4 (0.1--1.3)
   Severe: CCI score (\>5)                       0.9 (0.1--7.8)        0.8 (0.3--2.3)
  BGL group (reference: mild, 3.1--3.9 mmol/L)                         
   Moderate (2.3--3.0 mmol/L)                    0.8 (0.2--2.9)        1.2 (0.7--2.0)
   Severe (≤ 2.2 mmol/L)                         1 (0.3--3.9)          2.3 (1.2--4.2)^*a*^

ATSI, Aboriginal and Torres Strait Islander Australians; CI, confidence interval; HR, hazard ratio; NATSI, non-Aboriginal and Torres Strait Islander Australian; OR, odds ratio.

^*a*^ *P* \< 0.01.

^*b*^ *P* \< 0.05.

The results from multivariate Cox regression displayed in [Table 4](#T4){ref-type="table"} shows that being of ATSI origin is associated with longer LOS (HR, 2.1; 95% CI, 1.2-3.5). Having severe hypoglycemia (≤ 2.2 mmol/L) is significantly associated with longer LOS (HR, 2.3; 95 CI%, 1.2--4.2) than mild hypoglycemia (3.9-3.1 mmol/L). No significant differences in LOS were found for gender, age, and CCI score.

3. Discussion {#s3}
=============

To the best of our knowledge, this is the first study to estimate, in a hospital-based Australian diabetic population, incidence of inpatient hypoglycemia on general ward admissions. It shows a high rate of hypoglycemia, 29.9% in our cohort, which is much higher than the 3.5% to 10.5% reported by others \[[@CIT0009], [@CIT0013], [@CIT0014]\]. In our series, 70% of the study population were treated with insulin, in contrast to 24.5% reported by others in earlier studies \[[@CIT0008]\]. The relatively higher rate of insulin-treated patients in our series might have contributed to high incidence of inpatient hypoglycemia in our report. In support of our study, Umpierrez et al. \[[@CIT0015]\] reported similar incidence in their report on admitted insulin-treated type 2 diabetic patients, suggesting medication as a contributing factor. However, Malawana et al. and the International Hypoglycemia Study Group reported no significant differences in occurrence of inpatient hypoglycemia between insulin-treated and non-insulin-treated patients \[[@CIT0008], [@CIT0016]\].

We have also shown ATSI diabetic patients with inpatient hypoglycemia having significantly longer LOS compared with non-ATSI counterparts. Interestingly, as far as we know, this is the first report on association of increased LOS with ethnicity. Our finding is relevant in that ATSI people are 5.7 times more likely to be hospitalized for diabetes and thus at risk of long LOS, than non-Indigenous people \[[@CIT0001]\]. More research is needed to understand extent of racial differences in the association between inpatient hypoglycemia and LOS in the wider Australian diabetic population. This will assist in understanding other clinical and environmental risk factors to explain longer LOS among the diabetic ATSI patients. Future studies should assess avenues for addressing these potential causes of inpatient hypoglycemia in the indigenous diabetic inpatients and implement interventions to reduce hypoglycemia and LOS.

Our studies further highlight irrespective of ethnic background, severe hypoglycemia was associated with longer LOS as previously reported in the United Kingdom and United States \[[@CIT0009], [@CIT0012], [@CIT0017]\]. The need to maintain higher or normal BGLs is further supported by previous landmark studies showing excess mortality in individuals with tighter glycemic control compared with those with higher glycemic levels \[[@CIT0018], [@CIT0019]\]. Although increased mortality during and after admission was reported to be associated with inpatient hospital hypoglycemia \[[@CIT0017], [@CIT0020]\], there was no significant mortality in our cohort. The reason for this is not obvious, but might be due to a small sample size compared with earlier studies as well as high CCI, signifying high comorbidities in both subjects with and without hypoglycemia in our study population.

We have also shown older patients with inpatient hypoglycemia were less likely to be at risk of hospital readmission. Significance of this is not clear because readmission for other comorbidities as measured by CCI was not significant in our study. Despite Indigenous status with inpatient hypoglycemia being associated with long LOS, readmission within 1 month of initial hospital admission did not appear to be a contributory risk factor in diabetic ATSI subjects. This contrasts Zaccardi et al.'s report showing higher rate of readmissions among Caribbean diabetic subjects compared with Caucasians \[[@CIT0021]\]. In the same report, Asians (Bangladeshi, Pakistani, and Indian) were found to have lower risk of readmission compared with Caucasians thought to be due to less aggressive management of glucose in the Asian patients \[[@CIT0022]\]. More studies on a larger population in our setting is needed to characterize these findings.

Our data have an important strength: being, to the best of our knowledge, the first study to focus on Indigenous and non-Indigenous Australian patients with diabetes hospitalized in a general ward, by far the largest group of inpatients at high risk of hypoglycemia. On the other hand, some study limitations should be noted. The absence of randomization of patients in diabetic inpatient hypoglycemic group is an inherent problem in observational studies. Although we cannot be certain that hypoglycemia is the determining factor for LOS in the Indigenous and non-Indigenous cohort's analysis, matching the 2 patient groups on primary diagnosis and other background variables reduced confounding. In this retrospective study, although all patients had diabetes and were receiving antidiabetic medications including insulin, we cannot exclude the possibility that some non-antidiabetic medications and other conditions may have contributed to the inpatient hypoglycemia, for example, beta blockers, sepsis, or alcoholism, rather than antidiabetic medications alone. It is important to note that there is a limitation to retrospective studies in general. Observations derived from such studies may contain some missing information and thus may serve as a stimulus to further prospective work to clarify findings. Similarly, our study is based on a small sample of events, non-ATSI patients were twice higher than for ATSI patients, which is not surprising given that indigenous population is less than 10% of the local population \[[@CIT0023]\]. The present study must be interpreted in the knowledge of the defects inherent in such studies. Despite these, we believe that our report is likely to be accurate because experienced health care professionals made the recordings; our results are in line with similar findings in other non-Caucasian diabetic inpatient populations \[[@CIT0021]\].

4. Conclusion {#s4}
=============

Our results are significant for promoting awareness of the effect of ethnicity on inpatient hypoglycemia risk. Intensification of strategies for prevention of hypoglycemia including education, frequent glucose monitoring, and glycemic pattern recognition should be emphasized to minimize inpatient hypoglycemia, particularly in the identified high-risk indigenous population. Further prospective studies on a larger population are needed to verify our findings.
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